Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Early Phase 1
1(20.0%)
5Total
Phase 1(4)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05979857Early Phase 1Not Yet Recruiting

Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma

Role: lead

NCT03600649Phase 1Unknown

Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Role: lead

NCT05266196Phase 1Unknown

A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

Role: lead

NCT04611139Phase 1Withdrawn

Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers

Role: collaborator

NCT03895684Phase 1Completed

Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors

Role: lead

All 5 trials loaded